Entities

Capital Factory is an Austin-based venture firm founded in 2009 by Joshua Baer as a software accelerator. Its Texas Fund makes cash investments in deep and frontier technology, including AI, robotics, national security, healthcare, neurotechnology and next-generation industrial companies. All Access provides an equity-aligned network of advisors, introductions, customers and capital; an All Access portfolio listing alone does not prove participation in a particular cash financing. The current public team directory names eight professionals. Texas Fund launched in 2021, Fellowship Fund in 2023 and Texas Fund II opened in 2026. Texas Fund II reported USD7.2 million actually sold in its February23,2026 FormD, against a USD50 million offering target; that partial sale is not a final closing or a USD50 million raise. Capital Factory is distinct from STATION Austin, the nonprofit community initiative, and from unrelated similarly named financial entities.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Dalton Venture.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Fourier Intelligence.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Golden Falcon Capital.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Guosheng Capital.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Heal Capital.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Liepin.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Meridian Capital Asia.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Seas Capital.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: TsingSong Capital.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Action Potential Venture Capital.

Advent Life Sciences is a London-based life-sciences venture capital investor and company builder, managed by Advent Life Sciences LLP. It backs early innovation, often from seed or SeriesA, and works with founders on scientific and clinical development, operations, team building and financing. Its portfolio spans biotechnology, therapeutics, gene therapy, diagnostics and medical devices, including neuroscience-related companies Pheno Therapeutics, AviadoBio and Nalu Medical. The firm’s published team combines investment partners, scientific and clinical advisers, operating partners and finance and support staff.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Endeavour Vision.

Piper Heartland Healthcare Capital, LLC is an SEC-registered healthcare investment adviser within Piper Sandler, based in Minneapolis. It invests in biotechnology, medical technology and healthcare information companies, with a crossover strategy focused on businesses approaching public markets. Its stated strategy is to join investment syndicates without leading deals, to reduce conflicts with Piper Sandler clients. The flagship Piper Heartland Healthcare Crossover Fund I announced its final close in March2022 with more than USD200 million in committed capital; the exact final amount is unpublished. Fund II is separately listed in parent-company subsidiary filings, without a verified public closing size here. The current official leadership directory names Matt Hemsley, Ahmad El Naggar, Trent Holland and John Snodgrass. The firm is the Heartland Healthcare Capital named in Cleerly funding announcements and the Piper Heartland named in Saluda Medical financing; it is distinct from Piper Sandler Merchant Banking and unrelated Heartland Ventures.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: TMC Innovation.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: TPG Life Sciences.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: ASR Global Impact Equity Fund.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Alta Life Sciences.

CDTI is Spain’s Centro para el Desarrollo Tecnológico y la Innovación, E.P.E., a public business entity attached to the Ministry of Science, Innovation and Universities. It promotes innovation and technological development by Spanish businesses through technical and economic project evaluation, grants, loans with non-reimbursable portions, international technology cooperation, technology transfer and support for science-based startups. Its headquarters are in Madrid, with an international SOST office network serving Spanish companies. It is a public innovation agency rather than a private venture-capital partnership. The current governance framework is Royal Decree 263/2026 of 1 April. The published leadership scope comprises seven executives, the Consejo Rector’s president and director general plus thirteen members and its secretary, and twenty external strategic advisory council members. The advisory body supports the 2024–2027 strategic plan and does not establish permanent agency employment. Published ministry/agency job titles are retained for governing council representatives. Director biographies provide educational and professional experience for the seven executive members. Carlos de la Cruz’s current heading is Technology and Internationalisation, while the older biographical prose still mentions Technical Evaluation; the current heading takes precedence. CDTI is the sole shareholder of the distinct self-managed investment company Innvierte Economía Sostenible, SICC S.M.E., S.A., tax identifier A86510021. The existing CDTI-Innvierte institutional investor record represents that legal investment vehicle separately. Innvierte makes technology co-investments and invests in externally managed venture vehicles; its programme identity is not merged with the grant-making public agency. NEOTEC support is an agency programme rather than proof of an Innvierte equity subscription. A transaction’s literal CDTI wording is not blindly reassigned to the subsidiary without primary source qualification. The institution is relevant to AI, deep technology and neuroscience through its innovation instruments and actual sourced relationships with businesses such as INBRAIN Neuroelectronics and Anaconda Biomed. The September 2026 Anaconda financing explicitly distinguishes CDTI acting through its SICC Innvierte. Portfolio or programme affiliation does not prove an investment date, instrument, ticket or disbursement. Public budgets, available programme capacity, approved commitments, accounting share capital and private co-investor aggregate round totals are not represented as CDTI LP fund closes. The authentic combined ministry/government/CDTI logo is published by the official events site and respects the own identity guidance requiring the institutional combination. Genuine ministry-published portraits are available for Teresa Riesgo and José Moisés Martín; other directly associated executive image URLs are known but blocked by the CDTI site’s delivery protection in this research environment, and authentic portraits are not substituted. Public governance and adviser names are complete within the described published scope, not an inferred list of all 350-plus staff.

EQT Life Sciences is EQT’s specialist life-sciences investment platform, formerly Life Sciences Partners (LSP), which joined EQT in 2022. It backs innovative therapeutics, medical devices, diagnostics and digital-health companies, providing capital and scientific, clinical, operational and commercial support. Its strategies include core biotechnology funds investing across drug-development stages, Health Economics funds backing later-stage technologies that improve care while reducing costs, and a Dementia strategy developing treatments and medical technologies for neurodegenerative diseases. The platform’s public investment range is EUR10–60 million. Its strategy and advisory teams are distinct from the formal regulated fund managers and individual investment vehicles.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: MVM Partners.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Ottobock.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Loup Ventures.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: NXT Ventures.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Point Judith Capital.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Pureland Global Venture.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Synergy Ventures.

Named individual investor in sourced neurotechnology financing announcements. Original source name: Brian Shin. Firm affiliations do not imply a separate firm cheque.

Named individual investor in sourced neurotechnology financing announcements. Original source name: Tom Washing. Firm affiliations do not imply a separate firm cheque.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Ackman Oxman Institute.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: National Reconstruction Fund Corporation.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Project X.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Reliance Digital Health.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: General Advance.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: Subversive Capital.

Named investor or investing organization in sourced BCI/neurotechnology financing announcements. Manager/fund/legal vehicle scope is limited to the cited names; no undisclosed cheque sizes inferred. Original source name: University of Melbourne.

Named individual investor in sourced neurotechnology financing announcements. Original source name: Arani Bose. Firm affiliations do not imply a separate firm cheque.

Named individual investor in sourced neurotechnology financing announcements. Original source name: Ken Howery. Firm affiliations do not imply a separate firm cheque.

Chief of Staff at ScienceCorporation. Researched 2026-10-06. Source relationship: Aaron Bartnick — Current: Chief of Staff. Dossier: ScienceCorporation.md.

CTO and COO at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Alain Jordan — CTO and COO; current. Dossier: AbilityNeurotech.md.

Co-Founder, Chief Scientific Officer at ScienceCorporation. Researched 2026-10-06. Source relationship: Alan Mardinly, PhD — Current: Co-Founder, Chief Scientific Officer. Dossier: ScienceCorporation.md.

Co-founder at MergeLabs. Researched 2026-10-06. Source relationship: Alex Blania — Co-founder; pasted CEO role not independently established. Dossier: MergeLabs.md.

Chief Legal Officer at ScienceCorporation. Researched 2026-10-06. Source relationship: Alex Feerst, PhD — Current: Chief Legal Officer. Dossier: ScienceCorporation.md.

Scientific advisor at CorTec. Researched 2026-10-06. Source relationship: Alexander Mayr — Scientific advisor; current. Dossier: CorTec.md.

Chief Operating & Strategy Officer at MindMazeTherapeutics. Researched 2026-10-06. Source relationship: Alexandre Capet — Chief Operating & Strategy Officer; CEO December 2025–March 2026. Dossier: MindMaze.md.

Head strategy and corporate development at ONWARDMedical. Researched 2026-10-06. Source relationship: Alexandre Casteau — Current Head strategy and corporate development. Dossier: OnwardMedical.md.

Owner at Neurotechnology. Researched 2026-10-06. Source relationship: Algimantas Malickas — Parent sole owner; current disclosure; not automatically BrainAccess CEO. Dossier: BrainAccess.md.

CFO, joined January 2026 at ONWARDMedical. Researched 2026-10-06. Source relationship: Ali Kiboro — Current CFO, joined January 2026. Dossier: OnwardMedical.md.

senior finance director at ONWARDMedical. Researched 2026-10-06. Source relationship: Amori Fraser — Current senior finance director. Dossier: OnwardMedical.md.

Founder and CEO at Cognixion. Researched 2026-10-06. Source relationship: Andreas Forsland — Founder and CEO. Dossier: Cognixion.md.

Public team member (specific title undisclosed) at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Andreea-Alexandra Mavrodin, MSc — Public team member (specific title undisclosed). Dossier: AbilityNeurotech.md.

Historical VP Product (pre-2019 acquisition) at CTRLLabs. Researched 2026-10-06. Source relationship: Anthony Moschella — Historical VP Product. Historical role; not a current employment assertion. Dossier: CTRLLabs.md.

Director of Hardware and co-founder at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Arnau Espinosa — Director of Hardware and co-founder; current. Dossier: AbilityNeurotech.md.

Co-founder at Subsense. Co-founder named in February 2025 launch announcement; current operating role unverified.

Founder at CereGate. Researched 2026-10-06. Source relationship: Bálint Várkuti — Founder; historical CEO, still described as CEO in March 2024 press archive. Historical role; not a current employment assertion. Dossier: CereGate.md.

Historical CEO (July 2025–September 2026) at SaludaMedical. Researched 2026-10-06. Source relationship: Barry Regan — Former CEO (July2025–September2026). Dossier: SaludaMedical.md.

Historical COO (pre-2019 acquisition) at CTRLLabs. Researched 2026-10-06. Source relationship: Ben Jones — Historical COO. Historical role; not a current employment assertion. Dossier: CTRLLabs.md.

Founder / at BrainCo. Researched 2026-10-06. Source relationship: Han Bicheng / Bicheng Han (韩璧丞) — Founder / current CEO. Dossier: BrainCo.md. Founder at BrainRobotics. Researched 2026-10-06. Source relationship: Bicheng Han / Han Bicheng — Founder and historical CEO, 2020 speaker listing; current executive role unconfirmed. Historical role; not a current employment assertion. Dossier: BrainRobotics.md.

VP operations at ONWARDMedical. Researched 2026-10-06. Source relationship: Bob Odell — Current VP operations. Dossier: OnwardMedical.md.

CTO at MBrainTrain. Researched 2026-10-06. Source relationship: Bogdan Mijović — Current CTO; cofounder identity needs extra primary cross-check. Dossier: MBrainTrain.md.

President at CereGate. Researched 2026-10-06. Source relationship: Brian Blischak — Current President. Dossier: CereGate.md.

CEO Australia at ANTNeuro. Researched 2026-10-06. Source relationship: Caley Sullivan — Current CEO Australia. Dossier: ANTNeuro.md.

Director at CorTec. Researched 2026-10-06. Source relationship: Christoph Mangold — Director; current. Dossier: CorTec.md.

Chief Business Officer and co-founder at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Craig Cook — Chief Business Officer and co-founder; current. Dossier: AbilityNeurotech.md.

President at ScienceCorporation. Researched 2026-10-06. Source relationship: Darius Shahida — Current: President. Dossier: ScienceCorporation.md.

CEO at ONWARDMedical. Researched 2026-10-06. Source relationship: Dave Marver — Current CEO. Dossier: OnwardMedical.md.

Chief people officer at SaludaMedical. Researched 2026-10-06. Source relationship: David First — Chief people officer. Dossier: SaludaMedical.md.

Director of Software and co-founder at ABILITYNeurotech. Researched 2026-10-06. Source relationship: David Ibáñez Soria — Director of Software and co-founder; current. Dossier: AbilityNeurotech.md.

Medical Affairs leadership appointment December2025 at Neuralink. Researched 2026-10-06. Source relationship: David McMullen — Medical Affairs leadership appointment December2025. Dossier: Neuralink.md.

VP of Finance at ScienceCorporation. Researched 2026-10-06. Source relationship: Davin Hsieh — Current: VP of Finance. Dossier: ScienceCorporation.md.

CTO at SaludaMedical. Researched 2026-10-06. Source relationship: Dean Karantonis — CTO. Dossier: SaludaMedical.md.

Public team member (specific title undisclosed) at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Denis Rambaud, MSc — Public team member (specific title undisclosed). Dossier: AbilityNeurotech.md.

Global Head of Supply Chain at ANTNeuro. Researched 2026-10-06. Source relationship: Digvijay Wani — Current Global Head of Supply Chain. Dossier: ANTNeuro.md.

Sales VP / director at NeuracleMedicalTechnology. Researched 2026-10-06. Source relationship: Ding Jianfeng (丁剑峰) — Sales VP / director. Dossier: NeuracleMedicalTechnology.md.

General Manager EMEA at ANTNeuro. Researched 2026-10-06. Source relationship: Dominik Dietze — Current General Manager EMEA. Dossier: ANTNeuro.md.

Board chair at SaludaMedical. Researched 2026-10-06. Source relationship: Doug Godshall — Board chair. Dossier: SaludaMedical.md.

CEO UK at ANTNeuro. Researched 2026-10-06. Source relationship: Dylan Jones — Current CEO UK. Dossier: ANTNeuro.md.

Historical President and CEO (appointed April 2020) at NaluMedical. Researched 2026-10-06. Source relationship: Earl R. Fender — Historical president/CEO appointed April2020. Historical role; not a current employment assertion. Dossier: NaluMedical.md.

Co-Founder, Director of BCI Research at ScienceCorporation. Researched 2026-10-06. Source relationship: Emma Zhou — Current: Co-Founder, Director of BCI Research. Dossier: ScienceCorporation.md.

Board member at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Erwin Böttinger — Board member; current. Dossier: AbilityNeurotech.md.

Public team member (specific title undisclosed) at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Fabien Berrettoni, MSc — Public team member (specific title undisclosed). Dossier: AbilityNeurotech.md.

Head of Education at ANTNeuro. Researched 2026-10-06. Source relationship: Farnoosh Safavi — Current Head of Education. Dossier: ANTNeuro.md.

Public team member (specific title undisclosed) at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Florent Burdin, MSc — Public team member (specific title undisclosed). Dossier: AbilityNeurotech.md.

Chief Medical Officer, Ophthalmology at ScienceCorporation. Researched 2026-10-06. Source relationship: Frank Brodie, MD — Current: Chief Medical Officer, Ophthalmology. Dossier: ScienceCorporation.md.

CEO at CorTec. Researched 2026-10-06. Source relationship: Frank Desiere — CEO; current. Dossier: CorTec.md.

Board chair at NeuroPace. Researched 2026-10-06. Source relationship: Frank Fischer — Board chair; former CEO. Dossier: NeuroPace.md.

Founder at ANTNeuro. Researched 2026-10-06. Source relationship: Frank Zanow — Founder, historical; current CEO of related eemagine. Historical role; not a current employment assertion. Dossier: ANTNeuro.md.

Technology & AI lead at MindMazeTherapeutics. Researched 2026-10-06. Source relationship: Frédéric Condolo — Technology & AI lead, current. Dossier: MindMaze.md.

Gabriel Eichler is published by Atropos Health as life sciences advisory board member. Founder and Managing Director Oak Health Partners, fmr Novartis. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket. Existing separately sourced biography: Public team member (specific title undisclosed) at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Gabriel Eichler — Public team member (specific title undisclosed). Dossier: AbilityNeurotech.md.

R&D director at NeuracleMedicalTechnology. Researched 2026-10-06. Source relationship: Gong Changhui (龚昌辉) — R&D director. Dossier: NeuracleMedicalTechnology.md.

Scientific founder / advisor at ONWARDMedical. Researched 2026-10-06. Source relationship: Grégoire Courtine — Scientific founder; scientific advisor; left board July2025. Dossier: OnwardMedical.md.

Public team member (specific title undisclosed) at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Prof. Hagai Bergman — Public team member (specific title undisclosed). Dossier: AbilityNeurotech.md.

Director at CorTec. Researched 2026-10-06. Source relationship: Heiko Specht — Director; current. Dossier: CorTec.md.

Director at CorTec. Researched 2026-10-06. Source relationship: Helmut Jeggle — Director; current. Dossier: CorTec.md.

Cofounder at NeuracleMedicalTechnology. Researched 2026-10-06. Source relationship: Huang Xiaoshan (黄肖山) — Cofounder; current vice-chair / deputy general manager. Dossier: NeuracleMedicalTechnology.md.

Director at Neurotechnology. Researched 2026-10-06. Source relationship: Irmantas Naujikas — Director of parent; current contact listing. Dossier: BrainAccess.md.

CEO / cofounder at MBrainTrain. Researched 2026-10-06. Source relationship: Ivan Gligorijević — Current CEO / cofounder. Dossier: MBrainTrain.md.

Co-founder & CEO at MotifNeurotech. Researched 2026-10-06. Source relationship: Jacob Robinson — Co-founder & CEO, current. Dossier: MotifNeurotech.md.

CFO at ANTNeuro. Researched 2026-10-06. Source relationship: Jan Martijn Kors — Current CFO. Dossier: ANTNeuro.md.

Lead Neuroengineering / AI Solutions Architect at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Janir Ramos da Cruz — Lead Neuroengineering / AI Solutions Architect; current. Dossier: AbilityNeurotech.md.

Public team member (specific title undisclosed) at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Jérémie Martin, MSc — Public team member (specific title undisclosed). Dossier: AbilityNeurotech.md.

CFO at MindMazeTherapeutics. Researched 2026-10-06. Source relationship: Jeremy Meinen — CFO, current. Dossier: MindMaze.md.

CTO at ShanghaiActiveTechnology. Researched 2026-10-06. Source relationship: 贾婧 / Jia Jing — CTO confirmed by investor; chairman/legal representative in secondary registry. Dossier: ActiveTechnology.md.

Scientific advisor and co-founder at Axoft. Researched 2026-10-06. Source relationship: Jia Liu — Scientific advisor and co-founder; current. Dossier: Axoft.md.

SVP / President, Neuromodulation at BostonScientific. Researched 2026-10-06. Source relationship: Jim Cassidy — Current SVP / president Neuromodulation. Dossier: BostonScientificNeuromodulation.md. Jim Cassidy is president of Boston Scientific’s Neuromodulation business, leading therapies for chronic pain and movement disorders. The company’s own2026 announcements confirm his current division leadership and discuss peripheral-nerve stimulation, spinal cord stimulation and deep brain stimulation. An authentic original named company portrait accompanies its Relievant acquisition feature.

Scientific co-founder / medical advisor at ONWARDMedical. Researched 2026-10-06. Source relationship: Jocelyne Bloch — Scientific co-founder / medical advisor. Dossier: OnwardMedical.md.

General Counsel at ScienceCorporation. Researched 2026-10-06. Source relationship: Joe Mornin — Current: General Counsel. Dossier: ScienceCorporation.md.

CEO at NeuroPace. Researched 2026-10-06. Source relationship: Joel Becker — Current CEO. Dossier: NeuroPace.md.

Public team member (specific title undisclosed) at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Prof. José Millán — Public team member (specific title undisclosed). Dossier: AbilityNeurotech.md.

CFO at CereGate. Researched 2026-10-06. Source relationship: Joseph Doyle — Current CFO. Dossier: CereGate.md.

Director people and culture at ONWARDMedical. Researched 2026-10-06. Source relationship: Julie Crom — Current Director people and culture. Dossier: OnwardMedical.md.

VP engineering at ONWARDMedical. Researched 2026-10-06. Source relationship: Julien Camisani — Current VP engineering. Dossier: OnwardMedical.md.

CEO North America at ANTNeuro. Researched 2026-10-06. Source relationship: KC Chelette — Current CEO North America. Dossier: ANTNeuro.md.

Co-founder at NaluMedical. Researched 2026-10-06. Source relationship: Keegan Harper — Co-founder2014, former CEO; board chair last confirmed2020. Dossier: NaluMedical.md.

Director at CorTec. Researched 2026-10-06. Source relationship: Klaus Würtenberger — Director; current. Dossier: CorTec.md.

Head of Customer Success at ANTNeuro. Researched 2026-10-06. Source relationship: Krittika Choudhury — Current Head of Customer Success. Dossier: ANTNeuro.md.

Executive Vice President of Operations at ScienceCorporation. Researched 2026-10-06. Source relationship: Kylie Alsofrom — Current: Executive Vice President of Operations. Dossier: ScienceCorporation.md.

CFO / board secretary at NeuracleMedicalTechnology. Researched 2026-10-06. Source relationship: Li Jiabin (李嘉斌) — CFO / board secretary. Dossier: NeuracleMedicalTechnology.md.

Director / deputy general manager at NeuracleMedicalTechnology. Researched 2026-10-06. Source relationship: Liu Tao (刘涛) — Director / deputy general manager. Dossier: NeuracleMedicalTechnology.md.

VP legal at ONWARDMedical. Researched 2026-10-06. Source relationship: Lorenzo Fanti — Current VP legal. Dossier: OnwardMedical.md.

Director of Market Access at ScienceCorporation. Researched 2026-10-06. Source relationship: Marcus Simon — Current: Director of Market Access. Dossier: ScienceCorporation.md.

chief medical officer at NeuroPace. Researched 2026-10-06. Source relationship: Martha Morrell — Current chief medical officer. Dossier: NeuroPace.md.

CEO, ANT Neuro bv and GmbH at ANTNeuro. Researched 2026-10-06. Source relationship: Martijn Schreuder — Current CEO ANT Neuro bv and GmbH. Dossier: ANTNeuro.md.

Nonexecutive director at MindMazeTherapeutics. Researched 2026-10-06. Source relationship: Martin Reiss — Nonexecutive director, current. Dossier: MindMaze.md.

CTO and co-founder at CorTec. Researched 2026-10-06. Source relationship: Martin Schüttler — CTO and co-founder; current. Dossier: CorTec.md.

CEO / CTO at MELTINMMI. Current corporate profile names CEO/CTO Masahiro Kasuya. New corporation incorporated August 2024; legacy board not assumed current. Reviewed 2026-10-06.

Chief Product Officer at Axoft. Researched 2026-10-06. Source relationship: Matt DeNardo — Chief Product Officer; current. Dossier: Axoft.md.

CEO / managing director at CereGate. Researched 2026-10-06. Source relationship: Matthias Puls — Current CEO / managing director. Dossier: CereGate.md.

Director of Biohybrid Devices at ScienceCorporation. Researched 2026-10-06. Source relationship: Matthias Wagner — Current: Director of Biohybrid Devices. Dossier: ScienceCorporation.md.

Director of Operations at WearableSensing. Researched 2026-10-06. Source relationship: Melissa Poquette — Current Director of Operations; executive team since company origins. Dossier: WearableSensing.md.

Chairman and CEO at BostonScientific. Researched 2026-10-06. Source relationship: Michael F. Mahoney — Current parent chairman / CEO. Dossier: BostonScientificNeuromodulation.md. Michael F. Mahoney leads Boston Scientific as chairman and chief executive officer. His medical-device and healthcare-technology career includes earlier leadership of Johnson & Johnson’s medical-device and diagnostics businesses. He oversees the company’s global therapeutic portfolio and corporate strategy.

Co-founder at MergeLabs. Researched 2026-10-06. Source relationship: Mikhail Shapiro — Co-founder; Caltech professor. Dossier: MergeLabs.md.

Medical Director for BCI at ScienceCorporation. Researched 2026-10-06. Source relationship: Murat Günel, MD — Current: Medical Director for BCI. Dossier: ScienceCorporation.md.

Executive Vice President of Engineering at ScienceCorporation. Researched 2026-10-06. Source relationship: Nevada Sanchez — Current: Executive Vice President of Engineering. Dossier: ScienceCorporation.md.

COO at MotifNeurotech. Researched 2026-10-06. Source relationship: Nick Halper — COO, current. Dossier: MotifNeurotech.md.

Nonexecutive director at MindMazeTherapeutics. Researched 2026-10-06. Source relationship: Olaf Blanke — Nonexecutive director, current. Dossier: MindMaze.md.

Chief Clinical and Data Officer at Axoft. Researched 2026-10-06. Source relationship: Oliver Armitage — Chief Clinical and Data Officer; current. Dossier: Axoft.md.

CFO / COO at CorTec. Researched 2026-10-06. Source relationship: Oliver Bärtl — CFO / COO; current. Dossier: CorTec.md.

Director at CorTec. Researched 2026-10-06. Source relationship: Pascal Fries — Director; current. Dossier: CorTec.md.

Historical cofounder / CSO (pre-2019 acquisition) at CTRLLabs. Researched 2026-10-06. Source relationship: Patrick Kaifosh — Historical cofounder / CSO. Historical role; not a current employment assertion. Dossier: CTRLLabs.md.

CFO at NeuroPace. Researched 2026-10-06. Source relationship: Patrick Williams — Current CFO. Dossier: NeuroPace.md.

CEO and co-founder at Axoft. Researched 2026-10-06. Source relationship: Paul Le Floch — CEO and co-founder; current. Dossier: Axoft.md.

Director of Clinical Affairs at ScienceCorporation. Researched 2026-10-06. Source relationship: Ralf Hornig, PhD — Current: Director of Clinical Affairs. Dossier: ScienceCorporation.md.

Advisor at Subsense. Official advisor roster reviewed 2026-10-06; not executive employment.

Chief Communications Officer at ScienceCorporation. Researched 2026-10-06. Source relationship: Richard Socarides — Current: Chief Communications Officer. Dossier: ScienceCorporation.md.

Chairman and CEO at Abbott. Researched 2026-10-06. Source relationship: Robert B. Ford — Current parent chairman and CEO. Dossier: AbbottNeuromodulation.md.

CEO and co-founder at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Rotem Kopel — CEO and co-founder; current. Dossier: AbilityNeurotech.md.

VP Product Development at CereGate. Researched 2026-10-06. Source relationship: Saman Hagh Gooie — Current VP Product Development. Dossier: CereGate.md.

Founder at MotifNeurotech. Researched 2026-10-06. Source relationship: Sameer Sheth — Founder; current company founder profile. Dossier: MotifNeurotech.md.

Co-founder at MergeLabs. Researched 2026-10-06. Source relationship: Sandro Herbig — Co-founder. Dossier: MergeLabs.md.

chief commercial officer at ONWARDMedical. Researched 2026-10-06. Source relationship: Sean Sciara — Current chief commercial officer. Dossier: OnwardMedical.md.

Head of Marketing at ANTNeuro. Researched 2026-10-06. Source relationship: Sebastian Carstens — Current Head of Marketing. Dossier: ANTNeuro.md.

VP communications at ONWARDMedical. Researched 2026-10-06. Source relationship: Sébastien Cros — Current VP communications. Dossier: OnwardMedical.md.

Public team member (specific title undisclosed) at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Sébastien Menot, MSc — Public team member (specific title undisclosed). Dossier: AbilityNeurotech.md.

chief clinical, regulatory and quality officer at ONWARDMedical. Researched 2026-10-06. Source relationship: Shari O’Quinn — Current chief clinical, regulatory and quality officer. Dossier: OnwardMedical.md.

Head of External Affairs at ScienceCorporation. Researched 2026-10-06. Source relationship: Stephen Geer — Current: Head of External Affairs. Dossier: ScienceCorporation.md.

CTO at MotifNeurotech. Researched 2026-10-06. Source relationship: Steve Goetz — CTO, current. Dossier: MotifNeurotech.md.

Co-founder at MergeLabs. Researched 2026-10-06. Source relationship: Sumner Norman — Co-founder. Dossier: MergeLabs.md.

Founder at MotifNeurotech. Researched 2026-10-06. Source relationship: Sunil Sheth — Founder; current company founder profile. Dossier: MotifNeurotech.md.

Founder at MindMaze. Historical MindMaze founder, founded 2012. Not current successor CEO. Reviewed 2026-10-06.

Public team member (specific title undisclosed) at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Thierry Campiche — Public team member (specific title undisclosed). Dossier: AbilityNeurotech.md.

Board member at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Thomas Andrae — Board member; current. Dossier: AbilityNeurotech.md.

Scientific advisor at CorTec. Researched 2026-10-06. Source relationship: Thomas Stieglitz — Scientific advisor; current. Dossier: CorTec.md.

Public team member (specific title undisclosed) at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Tiago Bertolote, MSc — Public team member (specific title undisclosed). Dossier: AbilityNeurotech.md.

CTO and co-founder at Axoft. Researched 2026-10-06. Source relationship: Tianyang Ye — CTO and co-founder; current. Dossier: Axoft.md.

Historical cofounder & advisor (pre-2019 acquisition) at CTRLLabs. Researched 2026-10-06. Source relationship: Tim Machado — Historical cofounder & advisor. Historical role; not a current employment assertion. Dossier: CTRLLabs.md.

Historical President and CEO (2024) at NaluMedical. Researched 2026-10-06. Source relationship: Tom West — Historical president/CEO in2024; current post-acquisition role unverified. Historical role; not a current employment assertion. Dossier: NaluMedical.md.

Scientific advisor at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Tracy Laabs — Scientific advisor; current. Dossier: AbilityNeurotech.md.

Co-founder at MergeLabs. Researched 2026-10-06. Source relationship: Tyson Aflalo — Co-founder. Dossier: MergeLabs.md.

Scientific advisor at CorTec. Researched 2026-10-06. Source relationship: Ulf Ziemann — Scientific advisor; current. Dossier: CorTec.md.

Head of Quality and Regulatory at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Valerie Dubois — Head of Quality and Regulatory; current. Dossier: AbilityNeurotech.md.

Scientific advisor at CorTec. Researched 2026-10-06. Source relationship: Volker Coenen — Scientific advisor; current. Dossier: CorTec.md.

Nonexecutive chair at MindMazeTherapeutics. Researched 2026-10-06. Source relationship: Walid Hanna — Nonexecutive chair, current. Dossier: MindMaze.md.

founder & CEO at WearableSensing. Researched 2026-10-06. Source relationship: Walid Soussou — Current founder & CEO. Dossier: WearableSensing.md.

CEO Asia at ANTNeuro. Researched 2026-10-06. Source relationship: Wilson Chan — Current CEO Asia. Dossier: ANTNeuro.md.

Cofounder at NeuracleMedicalTechnology. Researched 2026-10-06. Source relationship: Xu Honglai (胥红来) — Cofounder; current chairman / general manager. Dossier: NeuracleMedicalTechnology.md.

CEO at MindMazeTherapeutics. Researched 2026-10-06. Source relationship: Zach Henderson — CEO, current (March 2026 onward). Dossier: MindMaze.md. PKG Health appointed Zach Henderson CEO and board director in May2023. Its primary biography identifies prior commercial leadership at Glooko and a career in healthcare software, analytics and life-science partnerships. The company explicitly announced his departure as CEO in February2025. This historical role is separate from his subsequently published MindMaze Therapeutics leadership.

CFO at ABILITYNeurotech. Researched 2026-10-06. Source relationship: Zooullis Mina — CFO; current. Dossier: AbilityNeurotech.md.

COO at SaludaMedical. Researched 2026-10-06. Source relationship: Aidan O’Sullivan — COO. Dossier: SaludaMedical.md.

Senior Research Scientist at Neurable. Researched 2026-10-06. Source relationship: Alicia Howell-Munson — Current public team: Senior Research Scientist. Dossier: Neurable.md.

Head of Partnerships at Subsense. Researched 2026-10-06. Source relationship: Amy Peck — Head of Partnerships, current. Dossier: Subsense.md.

Chief Strategy Officer at Subsense. Researched 2026-10-06. Source relationship: Andrew Ostarello — Chief Strategy Officer, current. Dossier: Subsense.md.

Head of Marketing / GTM Lead at Neurable. Researched 2026-10-06. Source relationship: Annika Helendi — Current public team: Head of Marketing / GTM Lead. Dossier: Neurable.md.

Acting Director, R&D Execution at Subsense. Researched 2026-10-06. Source relationship: Anthony Di Pasqua — Acting Director, R&D Execution, current. Dossier: Subsense.md.

Co-founder and Chief Evangelism Officer at Interaxon. Researched 2026-10-06. Source relationship: Ariel Garten — Co-founder and Chief Evangelism Officer; current. Dossier: Interaxon.md.

Lead Product Manager at Neurable. Researched 2026-10-06. Source relationship: Avi Horowitz — Current public team: Lead Product Manager. Dossier: Neurable.md.

VP, Head of Clinical and Science at Gestala. Researched 2026-10-06. Source relationship: Bashar W. Badran, Ph.D. — VP, Head of Clinical and Science. Dossier: Gestala.md.

Historical CTO (confirmed December 2024) at PrecisionNeuroscience. Researched 2026-10-06. Source relationship: Brian Otis — CTO named in Dec 2024; superseded by current grid listing Nate Pletcher. Dossier: PrecisionNeuroscience.md.

Advisor at Gestala. Researched 2026-10-06. Source relationship: Changjian Jiang — Advisor; Fudan associate professor. Dossier: Gestala.md.

Co-founder and Chief Innovation Officer at Interaxon. Researched 2026-10-06. Source relationship: Chris Aimone — Co-founder and Chief Innovation Officer; current. Dossier: Interaxon.md.

Founder / CEO at GTecMedicalEngineering. Researched 2026-10-06. Source relationship: Christoph Guger — Founder / CEO; company history supports ongoing leadership. Dossier: GtecMedicalEngineering.md.

Co-founder and CEO at OpenBCI. Researched 2026-10-06. Source relationship: Conor Russomanno — Co-founder and CEO. Dossier: OpenBCI.md.

Executive Chairman and CEO at Compumedics. Researched 2026-10-06. Source relationship: David Burton — Current Executive Chairman and CEO; founder. Dossier: Compumedics.md.

CFO & Company Secretary at Compumedics. Researched 2026-10-06. Source relationship: David Lawson — Current CFO & Company Secretary. Dossier: Compumedics.md.

VP Regulation and Quality at Gestala. Researched 2026-10-06. Source relationship: David (Dudu) Rigler — VP Regulation and Quality. Dossier: Gestala.md.

Technical Director, AI/ML at Neurable. Researched 2026-10-06. Source relationship: David Stanley — Current public team: Technical Director, AI/ML. Dossier: Neurable.md.

Founding team member (2021) at PrecisionNeuroscience. Researched 2026-10-06. Source relationship: Demetrios Papageorgiou — 2021 founding team; current role not verified. Dossier: PrecisionNeuroscience.md.

Executive Coordinator at Neurable. Researched 2026-10-06. Source relationship: Erin Scott — Current public team: Executive Coordinator. Dossier: Neurable.md.

VP of Business Development at Neurable. Researched 2026-10-06. Source relationship: Eugene Goldberg — Current public team: VP of Business Development. Dossier: Neurable.md.

Chairman and CEO at Medtronic. Researched 2026-10-06. Source relationship: Geoff Martha — Current parent chairman / CEO. Dossier: MedtronicNeuromodulation.md.

Cofounder / CEO at GTecMedicalEngineering. Researched 2026-10-06. Source relationship: Günter Edlinger — Cofounder / CEO; company history supports ongoing leadership. Dossier: GtecMedicalEngineering.md.

CFO at SaludaMedical. Researched 2026-10-06. Source relationship: James Erickson — CFO. Dossier: SaludaMedical.md.

Cofounder / CSO at Bitbrain. Researched 2026-10-06. Source relationship: Javier Mínguez — Cofounder / CSO; current role corroborated by university 2024 event. Dossier: Bitbrain.md.

CEO at Interaxon. Researched 2026-10-06. Source relationship: Jean-Michel Fournier — CEO; current. Dossier: Interaxon.md.

Scientific advisory board at Gestala. Researched 2026-10-06. Source relationship: Jianfeng Feng, Ph.D. — Scientific advisory board. Dossier: Gestala.md.

Senior Hardware Engineer at Neurable. Researched 2026-10-06. Source relationship: Jim Wright — Current public team: Senior Hardware Engineer. Dossier: Neurable.md.

Co-founder at OpenBCI. Researched 2026-10-06. Source relationship: Joel Murphy — Co-founder; current executive role not established. Dossier: OpenBCI.md.

Business Development Manager, Defense at Neurable. Researched 2026-10-06. Source relationship: Johan Restrepo — Current public team: Business Development Manager, Defense. Dossier: Neurable.md.

Historical President and Chief Commercial Officer (2023) at OpenBCI. Researched 2026-10-06. Source relationship: Joseph Artuso — President and Chief Commercial Officer in 2023 company announcement. Dossier: OpenBCI.md.

Staff Software Engineer at Neurable. Researched 2026-10-06. Source relationship: Joshua Zosky — Current public team: Staff Software Engineer. Dossier: Neurable.md.

Chief legal officer at SaludaMedical. Researched 2026-10-06. Source relationship: Kristin Caplice — Chief legal officer. Dossier: SaludaMedical.md.

EVP / President, Neuroscience at Medtronic. Researched 2026-10-06. Source relationship: Kweli Thompson — Current EVP/president Neuroscience; June2026. Dossier: MedtronicNeuromodulation.md.

Vice President of Engineering at Neurable. Researched 2026-10-06. Source relationship: Lindsay Nie — Current public team: Vice President of Engineering. Dossier: Neurable.md.

Historical CTO (2022) at Bitbrain. Researched 2026-10-06. Source relationship: Luis Montesano — Historical CTO in 2022; current employment not established. Historical role; not a current employment assertion. Dossier: Bitbrain.md.

VP of Quality and Regulatory Affairs at Paradromics. Researched 2026-10-06. Source relationship: Lydia Hancock — Current: VP of Quality and Regulatory Affairs. Dossier: Paradromics.md.

CTO at Interaxon. Researched 2026-10-06. Source relationship: Marcela Guerra — CTO; current. Dossier: Interaxon.md.

Cofounder / CEO at Bitbrain. Researched 2026-10-06. Source relationship: María López-Valdés — Cofounder / CEO; public government interview. Dossier: Bitbrain.md.

VP Research and Development, appointed August2025 at Synchron. Researched 2026-10-06. Source relationship: Mark Brister — VP Research and Development, appointed August2025. Dossier: Synchron.md.

Executive VP of Finance at Paradromics. Researched 2026-10-06. Source relationship: Matt Marino — Current: Executive VP of Finance. Dossier: Paradromics.md.

CEO at SaludaMedical. Researched 2026-10-06. Source relationship: Mike Mathias — Current CEO; September2026 appointment. Dossier: SaludaMedical.md.

Chief Marketing Officer at Interaxon. Researched 2026-10-06. Source relationship: Nadia Kumentas — Chief Marketing Officer; current. Dossier: Interaxon.md.

Head of AI at Subsense. Researched 2026-10-06. Source relationship: Parminder Mankoo — Head of AI, current. Dossier: Subsense.md.

Senior Research Scientist at Neurable. Researched 2026-10-06. Source relationship: Pawan Lapborisuth — Current public team: Senior Research Scientist. Dossier: Neurable.md.

Founder / CEO at Gestala. Researched 2026-10-06. Source relationship: Phoenix Peng, Ph.D. — Founder / CEO. Dossier: Gestala.md.

VP of Implantable Technology at Gestala. Researched 2026-10-06. Source relationship: Ra'anan Gefen — VP of Implantable Technology. Dossier: Gestala.md.

Chief Financial Officer at Neurable. Researched 2026-10-06. Source relationship: Reid Van Gorder — Current public team: Chief Financial Officer. Dossier: Neurable.md.

non-executive director at Compumedics. Researched 2026-10-06. Source relationship: Rod North — Current non-executive director on official people page. Dossier: Compumedics.md.

Senior R&D Director at Subsense. Researched 2026-10-06. Source relationship: Rose Monaghan — Senior R&D Director, current. Dossier: Subsense.md.

CEO / CTO at KernelNeurotech. Researched 2026-10-06. Source relationship: Ryan Field — Former CEO/CTO; departed 2026-08-28. Dossier: KernelNeurotech.md.

Head of Operations at Subsense. Researched 2026-10-06. Source relationship: Sasha Isaenko — Head of Operations, current. Dossier: Subsense.md.

Head of R&D & co-founder at Subsense. Researched 2026-10-06. Source relationship: Scott Meek — Head of R&D & co-founder, current. Dossier: Subsense.md.

General Counsel at Paradromics. Researched 2026-10-06. Source relationship: Scott Way — Current: General Counsel. Dossier: Paradromics.md.

Principal Firmware Engineer at Neurable. Researched 2026-10-06. Source relationship: Shruthi Gujjula — Current public team: Principal Firmware Engineer. Dossier: Neurable.md.

VP of People at Paradromics. Researched 2026-10-06. Source relationship: Sofi Hoysal — Current: VP of People. Dossier: Paradromics.md.

Founder and Chairman at NeuroSky. Researched 2026-10-06. Source relationship: Stanley Yang — Founder and Chairman, March 2026; historical CEO. Historical role; not a current employment assertion. Dossier: NeuroSky.md.

Program Manager, Strategic Partnership at Neurable. Researched 2026-10-06. Source relationship: Tessa Sharma — Current public team: Program Manager, Strategic Partnership. Dossier: Neurable.md.

CEO & co-founder at Subsense. Researched 2026-10-06. Source relationship: Tetiana Aleksandrova — CEO & co-founder, current. Dossier: Subsense.md.

Chief of Staff at Interaxon. Researched 2026-10-06. Source relationship: Tracy Brown — Chief of Staff; current. Dossier: Interaxon.md.

Scientific advisory board at Gestala. Researched 2026-10-06. Source relationship: Trevor Robbins, Ph.D. — Scientific advisory board. Dossier: Gestala.md.

Principal Research Engineer at Neurable. Researched 2026-10-06. Source relationship: Walter Piper — Current public team: Principal Research Engineer. Dossier: Neurable.md.

CTO at Compumedics. Researched 2026-10-06. Source relationship: Warwick Freeman — Current CTO on official people page. Dossier: Compumedics.md.

Program Manager, Sales and Customer Success at Neurable. Researched 2026-10-06. Source relationship: Zachary Phillips — Current public team: Program Manager, Sales and Customer Success. Dossier: Neurable.md.

Lead Hardware & Electronics at IDUNTechnologies. Researched 2026-10-06. Source relationship: Andrea Fümm — Lead Hardware & Electronics; current website listing. Dossier: IdunTechnologies.md.

Kandu Chief Commercial Officer at Kandu. Researched 2026-10-06. Source relationship: Andy Schultz — Current Kandu Chief Commercial Officer. Dossier: Neurolutions.md.

Sr. Business Developer at IDUNTechnologies. Researched 2026-10-06. Source relationship: Anthony Rodrick — Sr. Business Developer; current website listing. Dossier: IdunTechnologies.md.

Fullstack Developer at IDUNTechnologies. Researched 2026-10-06. Source relationship: Bogdan Pistol — Fullstack Developer; current website listing. Dossier: IdunTechnologies.md.

Data Scientist at IDUNTechnologies. Researched 2026-10-06. Source relationship: Chléa Schiff — Data Scientist; current website listing. Dossier: IdunTechnologies.md.

Co-founder at Neurolutions. Researched 2026-10-06. Source relationship: Daniel Moran — Neurolutions cofounder; historical. Historical role; not a current employment assertion. Dossier: Neurolutions.md.

Founder at Neurolutions. Researched 2026-10-06. Source relationship: Eric Leuthardt — Neurolutions founder; historical scientific leadership. Historical role; not a current employment assertion. Dossier: Neurolutions.md.

Board Member at IDUNTechnologies. Researched 2026-10-06. Source relationship: Illka Korhonen — Board Member; current website listing. Dossier: IdunTechnologies.md.

Kandu COO at Kandu. Researched 2026-10-06. Source relationship: Javad Seyedzadeh — Current Kandu COO. Dossier: Neurolutions.md.

Lead Material at IDUNTechnologies. Researched 2026-10-06. Source relationship: Dr. Katja Junker — Lead Material; current website listing. Dossier: IdunTechnologies.md.

Kandu General Manager and CMO at Kandu. Researched 2026-10-06. Source relationship: Kirsten Carroll — Current Kandu General Manager and CMO; former Kandu Health founder/CEO. Dossier: Neurolutions.md.

Kandu CEO / director at Kandu. Researched 2026-10-06. Source relationship: Leo Petrossian — Current Kandu CEO / director. Dossier: Neurolutions.md.

Product Development Engineer at IDUNTechnologies. Researched 2026-10-06. Source relationship: Luana Gisler — Product Development Engineer; current website listing. Dossier: IdunTechnologies.md.

Lead Product Design at IDUNTechnologies. Researched 2026-10-06. Source relationship: Dr. Mark Melnykowycz — Lead Product Design; current website listing. Dossier: IdunTechnologies.md.

CTO at IDUNTechnologies. Researched 2026-10-06. Source relationship: Dr. Moritz Thielen — CTO; current website listing. Dossier: IdunTechnologies.md.

Kandu CFO at Kandu. Researched 2026-10-06. Source relationship: Nabeel Ahmed — Current Kandu CFO. Dossier: Neurolutions.md.

Lead Data Scientist at IDUNTechnologies. Researched 2026-10-06. Source relationship: Dr. Philip Egger — Lead Data Scientist; current website listing. Dossier: IdunTechnologies.md.

Kandu Chief Innovation Officer at Kandu. Researched 2026-10-06. Source relationship: Seth Wilk — Current Kandu Chief Innovation Officer. Dossier: Neurolutions.md.

Co-Founder & CCO at IDUNTechnologies. Researched 2026-10-06. Source relationship: Séverine Gisin — Co-Founder & CCO; current website listing. Dossier: IdunTechnologies.md.

Co-Founder & CEO at IDUNTechnologies. Researched 2026-10-06. Source relationship: Simon Bachmann — Co-Founder & CEO; current website listing. Dossier: IdunTechnologies.md.

Board Member at IDUNTechnologies. Researched 2026-10-06. Source relationship: Simon Meier — Board Member; current website listing. Dossier: IdunTechnologies.md.

Machine Learning & Software Engineer at IDUNTechnologies. Researched 2026-10-06. Source relationship: Yu Min Chuang — Machine Learning & Software Engineer; current website listing. Dossier: IdunTechnologies.md.

Historical MindMaze neurotechnology group founded by Tej Tadi. Strategic assets and brand transferred to NeuroX during restructuring, followed by a December 2025 combination with Relief Therapeutics. Current operating successor is MindMaze Therapeutics; original financing is not successor capital.

AI researcher and engineer associated with Tilde Research, as listed on his public LinkedIn profile. Studies computer science at Stanford. Exact Tilde title and tenure are not publicly visible.

AI research lab studying mechanistic interpretability, model architectures and pretraining to understand and improve intelligent systems.

Investor named as Timeless in Tilde Research’s seed financing announcement. Full legal name and website have not been verified.

Machine learning researcher at Tilde Research in San Francisco; previously worked at the Vector Institute.

Researcher affiliated with Tilde Research; coauthor of Aurora, Compositional Muon and Wall Attention.

Co-founder and CEO of Tilde Research; also publishes as Ben Keigwin.

Core contributor and corresponding author of Tilde’s MoMoE release in July 2025. Current employment status is not publicly confirmed.

Co-founder and chief scientist of Tilde Research, working on pretraining and learning dynamics.

Tilde research contributor on Aurora and Compositional Muon. Tilde’s company page lists him among employees; his individual LinkedIn currently lists Google DeepMind, so current employment status is unresolved.

Former co-founder and CTO of Tilde Research, where he led engineering and infrastructure. His current website lists ML work at Neuralink. Departure date is undisclosed.

Previously worked on applied interpretability research at Tilde Research. His current personal website lists ML research at Kimi Moonshot. Departure date is undisclosed.

Research engineer contributing to Tilde’s attention mechanisms and high-performance ML kernels, including MoMoE and Popcorn.

Named backer of Tilde Research. Investment amount and round are not disclosed.

Deyta is a portfolio company of Inovo.vc.

Lute is a portfolio company of Inovo.vc.

Builds a mobile social platform for creating, playing and sharing short casual games. Users describe a game to an AI creation tool, remix existing games and discover playable creations in a swipeable feed. Games run inside the platform without separate downloads; its tools also support making games in Discord chats.

Navigara is a portfolio company of Inovo.vc.

Creem provides payments, billing and monetisation infrastructure for software businesses, including merchant-of-record services and tools for AI-native products.

AI Clearing is an Inovo.vc portfolio company focused on AI, Data Science, Construction.

Ahoy is an Inovo.vc portfolio company focused on Other.

Eyerim is an Inovo.vc portfolio company focused on Ecommerce.

Index Health is an Inovo.vc portfolio company focused on Healthcare.

Infermedica is an Inovo.vc portfolio company focused on Healthcare, AI, Data Science.

LiveKid is an Inovo.vc portfolio company focused on EdTech.

Moregrowth is an Inovo.vc portfolio company focused on Other.

Pathway is an Inovo.vc portfolio company focused on AI, Data Science.

Pupilmed is an Inovo.vc portfolio company focused on Healthcare.

London-based software company developing an AI formulation assistant for chemical and materials research and development. Its platform uses Bayesian optimization to guide experimental design: researchers define project objectives, input experimental data and receive suggestions for which formulations or process settings to test next. Analytics help teams interpret results and refine their approach over successive experiments. Published applications include inks, paints and coatings, specialty chemicals, pharmaceutical formulation with excipients, synthesis-route optimization and process optimization. The product supports laboratory R&D decisions through software and machine learning.

Restaumatic is an Inovo.vc portfolio company focused on Food.

Spacelift is an Inovo.vc portfolio company focused on Developer Tools.

Sunroof is an Inovo.vc portfolio company focused on Energy.

Tidio is an Inovo.vc portfolio company focused on Chatbots.

AI design software company founded in 2024 by Ukrainian designers and developers. Its canvas-based tool turns natural-language prompts, product requirements, screenshots and design references into editable multi-screen interfaces and clickable prototypes for mobile and desktop products. Users refine layouts, colors, typography and components through chat or manual editing, then share designs or export them to Figma, HTML/CSS and images. Brand references help keep generated screens consistent with a product’s visual style, while MCP connections let coding agents access the designs. Banani serves product managers, founders, engineers and designers moving from ideas to user interfaces.

Evidose is an Inovo.vc portfolio company focused on Healthcare.

Fieldy is an Inovo.vc portfolio company focused on Productivity.

Gralio.ai is an Inovo.vc portfolio company focused on AI, Data Science.

Handwave is an Inovo.vc portfolio company focused on Fintech.

AI and computational biology company developing a Biological Reasoning Engine for pharmaceutical research and development. Its Modality Fusion architecture integrates models and representations across biological scales, from molecules to patients, and combines clinical data, omics, scientific literature, imaging and biological pathways. The engine produces mechanistic hypotheses, step-by-step reasoning and evidence chains with source provenance to help research teams prioritize experiments, biomarkers, drug designs and clinical positioning. Examples include antibody-drug conjugate design prioritization, translational evidence synthesis and comparison of drug assets. The company offers a Qualified Access Program for partners bringing translational and clinical research questions; its outputs support scientific decision-making and experimental validation.

Mindly is an Inovo.vc portfolio company focused on Healthcare.

mysite.ai is an Inovo.vc portfolio company focused on AI, Data Science.

Quantia is an Inovo.vc portfolio company focused on AI, Data Science.

Quesma is an Inovo.vc portfolio company focused on Developer Tools.

RiskSeal is an Inovo.vc portfolio company focused on Data.

SmartSchool is an Inovo.vc portfolio company focused on EdTech.

Splx.ai is an Inovo.vc portfolio company focused on Cybersecurity, AI, Data Science.

UK-founded AI software company serving financial analysts, consultants, investment banks, private equity firms and corporate finance teams. Its platform adapts large language models to quantitative spreadsheet work and connects AI agents to Excel, PowerPoint and Word. Users can build, review and stress-test financial models, check formulas and errors, reconcile source data, analyze deal assumptions and create presentations or interactive web deliverables. Projects retain chats, files and versioned outputs with citations and action logs so analysts can trace and validate the work. Tracelight supports due diligence, mergers and acquisitions, valuation, underwriting and corporate development workflows.

Venture Partner at Inovo.vc and SaaS specialist who works with companies as an active chairman or board member. Supports product development, sales, marketing, hiring and go-to-market execution. Helped develop the Microsoft accelerator in Israel and the Kama Tech accelerator.

Venture Partner at Inovo.vc with experience in e-commerce, fintech, payments, retail and online services. His background includes commercial and board leadership at Allegro during its IPO, leadership roles at First Data Poland and Loyalty Partner, and a partnership at McKinsey & Company. Specializes in general management, business development and commercial strategy.

Operations and Administration Manager at Inovo.vc. Started as Office Manager and now focuses on daily operations, events, team support and organizing team-building activities and offsites.

Legal Counsel at Inovo.vc, based in Kraków. Joined in May 2023 after five years as a lawyer at another Polish venture capital fund. Handles fund governance, investment and exit structuring, negotiations, due diligence and regulatory compliance, with experience in transactions across Europe and the US.

Responsible for investor relations and fundraising at Inovo.vc since joining in 2019. Previously spent nearly a decade in banking and wealth management at ING, BNP Paribas and Noble Bank. Also made angel investments in Wedding.pl and FitAdept. Focuses on relationships with the firm's limited partners.

Partner and CFO at Inovo.vc. Joined as CFO in October 2022 and oversees finance, fund reporting, tax, legal coordination, back-office operations and investment processes. Previously worked in consulting, private equity and real estate, building experience in finance, accounting and financial management.

Analyst at Inovo.vc supporting the sourcing and evaluation of early-stage startups. Interested in AI SaaS, future of work, digital health and consumer technology, especially applications of AI in healthcare and productivity.

Principal at Inovo.vc, which he joined in late 2022. Focuses on B2B SaaS, marketplaces, consumer and small-business products, with an interest in the Baltics. Sources investments and supports portfolio companies with financial analysis, dashboards and analytics.

Partner at Inovo.vc focused on AI, data science and deep tech. Previously co-founded B2B marketplace Cateringoo and served as COO at data infrastructure startup Oxla and AI climate insurtech Climatica. Also worked at venture builder Daftcode and in technology M&A and venture investing.

Partner at Inovo.vc investing in developer tools, DevOps, infrastructure, deep tech and B2B enterprise software. Works with technical founders on products, business strategy and fundraising. His portfolio includes Spacelift, Archbee, AI Clearing and Eyerim. Member of Kauffman Fellows Class 26.

Partner at Inovo.vc focused on healthcare, B2C, B2B2C, SME software and SaaS-enabled marketplaces. Helps founders with sales, marketing and company growth. His background spans strategic consulting, building online businesses and FMCG marketing. Inovo's portfolio credits him with investments including Booksy, Preply, Infermedica, Tidio and Jutro Medical.

Managing Partner at Inovo.vc, leading the team and backing CEE founders building global technology businesses. Focuses on B2B enterprise companies, repeat founders and expansion into the US. Previously worked in investment banking at Rothschild and private equity at Penta. His Inovo portfolio includes Symmetrical, Intiaro, Packhelp and Restaumatic.

Coauthor of Aleph Neuro's July 2026 silent-speech ultrasound research. His personal site reports two International Olympiad in Informatics gold medals. Employment at Aleph is not established by the available sources.

Co-founder of Aleph Neuro working on ultrasound brain imaging. Research and engineering projects include silent-speech decoding from tongue ultrasound, olfactory stimulation and computational neuroscience. Studied at Ecole Polytechnique.

Coauthor of Aleph Neuro's July 2026 silent-speech ultrasound research. Founder of Silent Technologies and previously built Vox Lab. The Aleph relationship is verified research collaboration; employment status is not established.

Aleph Neuro is a San Francisco research company developing ultrasound-based brain interfaces, led by cofounders Marley Xiong (CEO), Raffi Hotter and Lev Chizhov. Its long-term aim is richer communication through non-invasive neural interfaces. Research: In June 2026 the company reported high-resolution 3D imaging of human brain vasculature through an intact skull using injected microbubble contrast and released its processing pipeline. Contrast-free neurovascular imaging and general-purpose neural decoding remain research goals. In July 2026 it reported a tongue-ultrasound silent-speech prototype with 15.6% word error rate on its internal cross-speaker validation set after training on about 50 hours of data. This prototype reads tongue motion; it is not demonstrated thought decoding. Hardware miniaturization, coupling material and accent generalization remain limitations. Butterfly Network supplies an ultrasound platform through its Embedded licensing/co-development program. Research collaborators named on Aleph posts include Vadims Casecnikovs and Gimran Abdullin (silent speech), and Albert Yan-Huang, Thomas Ribeiro and Aayush Gupta (olfactory stimulation); these credits alone do not establish employee status. Funding research (September 21, 2026): No confirmed Aleph Neuro equity investors, round dates or amounts were found. Moth Fund lists Alegria Neurotech, founded by Hotter and Xiong, in its MF I portfolio; the relationship between that entity and Aleph remains unverified. Magnificent Grants previously supported Xiong and Hotter's neural-imagery research through a fellowship. Neither that founder-level grant nor Butterfly's commercial partnership is recorded as an Aleph equity investment.

Co-founder and CEO of Aleph Neuro, developing ultrasound-based brain interfaces. Previously studied at McGill and worked on neurotechnology research; public research includes brain-controlled interfaces and visual-imagery decoding.

Co-founder of Aleph Neuro. Previously built neurotechnology instrumentation in Adam Cohen's lab at Harvard and worked on neurotechnology at Google X. Studied mathematics, computer science and physics; projects include a brain-controlled wheelchair and Curius.

Managing Partner at Cambridge Innovation Capital Andrew Williamson is listed by Cambridge Innovation Capital as managing partner. Managing partner since 2019, with previous Physic Ventures and True North experience; earned a Cambridge physics doctorate and Berkeley MBA. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets. Andrew Williamson has been CIC managing partner since2019, with prior venture roles at Physic Ventures and True North. He has a Cambridge physics PhD and a Berkeley MBA. The official registry names Andrew James Williamson as a director of Start Codon Ltd and Start Codon General Partner Ltd since25January2025. Andrew Williamson is a published Xfund faculty/advisory affiliate. The directory supplies this professional context: Andrew Williamson Managing Partner, Cambridge Innovation Capital. This undated published affiliation is scoped to the Xfund advisory/community network; it does not establish an investment-partner appointment, cash contribution, personal check or independently verified current outside employment.

Senior Investment Associate at Cambridge Innovation Capital

Partner at Cambridge Innovation Capital Robert Tansley is listed by Cambridge Innovation Capital as venture partner. Physician and life-science investor with previous Sanofi, MHRA, Roche and Arakis work; CIC’s individual profile now identifies him as Venture Partner. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Partner & CFO at Cambridge Innovation Capital Rob Sprawson is listed by Cambridge Innovation Capital as partner and cfo. Finance executive with previous Altacor, Warwick Ventures and PwC experience. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets. Rob Sprawson is CIC partner and CFO, with experience in life-sciences and technology finance, previous CFO roles at Altacor and Warwick Ventures, and PwC corporate-finance work. He is an ICAEW fellow. Companies House names Robert Timothy Sprawson as a current director of Start Codon Ltd and its GP appointed25January2025.

Non Executive Director at Cambridge Innovation Capital

Partner at Cambridge Innovation Capital

Partner at Cambridge Innovation Capital Ian Lane is listed by Cambridge Innovation Capital as partner. Technology investment partner with previous Unilever Ventures, B2B technology and LEK Consulting experience. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Associate at Cambridge Innovation Capital Edward Inns is listed by Cambridge Innovation Capital as principal. Technology principal with previous Williams/Foresight investment experience; works across robotics, AI and semiconductors and holds a Cambridge doctorate in biomaterials. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Partner at Cambridge Innovation Capital Anne Horgan is listed by Cambridge Innovation Capital as partner. Life-science investment partner with previous AdBio and Sofinnova experience and a medicinal-chemistry background including cancer research. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets. Anne Horgan is CIC life-sciences partner. Her current CIC biography expressly identifies management of the Start Codon portfolio, separately from her parent-manager employment. She has earlier AdBio/Sofinnova investment and medicinal-chemistry experience, a Bristol synthetic-organic-chemistry doctorate and Yale postdoctoral research.

Partner at Cambridge Innovation Capital Michael Anstey is a TRIMTECH non-executive director and Cambridge Innovation Capital life-sciences partner. Earlier roles include Boston Consulting Group and Oxford Capital Partners. He earned an Oxford doctorate in neurobiology. His institutional board affiliation is distinct from preserved personal investment-history records. Michael Anstey is listed by Cambridge Innovation Capital as partner. Life-science investment partner with previous BCG and Oxford Capital experience and an Oxford doctorate in neurobiology. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets. Michael Anstey is CIC life-sciences partner with Oxford neurobiology doctoral training and previous BCG and Oxford Capital investment experience. His Start Codon Ltd directorship is historical,15April2019–25January2025, distinct from his current TRIMTECH board and parent CIC roles.

Partner at Zetta Venture Partners

General Partner at Zetta Venture Partners

Managing Director at Zetta Venture Partners

Managing Director at Zetta Venture Partners

Partner at Zetta Venture Partners

Managing Partner at Zetta

Managing Director at Zetta Venture Partners

Founding Partner at Wing Venture Capital

Co-Founder & General Partner at Work-Bench

General Partner at Work-Bench

Partner at Wing Venture Capital

Partner at Wing

Partner at Wing Venture Capital

Founding Partner at Wing Venture Capital

Partner at Wing Venture Capital

General Partner at Vsquared Ventures

General Partner at White Star Capital

General Partner at White Star Capital

Managing Partner at White Star Capital

General Partner at White Star Capital

General Partner at White Star Capital

Founder & Managing Partner at White Star Capital

General Partner at White Star Capital

Principal at White Star Capital

General Partner & Chief Catalyst Officer at White Star Capital

General Partner at White Star Capital

Venture Partner at White Star Capital

General Partner @ White Star Capital

Venture Guide, Managing Partner at Venture Guides

Venture Partner at Vsquared Ventures

General Partner at Version One Ventures

founder & general partner at Version One Ventures

General Partner at Vsquared Ventures

Kiutra lists Michael Jobst in its Board and advisors directory as its 55 North representative. The issuer explicitly identifies him as a board member.

General Partner at Vsquared Ventures

Managing Partner at VentureFriends

Technical Advisor at Venture Guides